(4-isobutylphenyl)propionate | 950994-33-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: (4-isobutylphenyl)propionate
• 英文别名: (p-isobutylphenyl)propanoate；[4-(2-Methylpropyl)phenyl] propanoate
• CAS: 950994-33-9
• 化学式: C₁₃H₁₈O₂
• 分子量: 206.285
• InChiKey: GDEWWRSTAFJRRQ-UHFFFAOYSA-N

物化性质

• 沸点：
  282.2±19.0 °C(Predicted)
• 密度：
  0.983±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-溴苯基丙酸酯 、 叔丁基氯化镁 在 bis(acetylacetonate)nickel(II) 、 1-(2-carboxyethyl)-3-mesityl-1H-imidazol-3-ium chloride 、 lithium tert-butoxide 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 0.17h， 生成 (4-isobutylphenyl)propionate 、 (4-叔丁基苯基)丙酸酯
  参考文献：
  名称：

  利用供体功能化的N-杂环卡宾（NHC）进行的镍催化的芳基溴化物与叔格氏试剂的交叉偶联

  摘要：

  一二三 空间位阻烷基底物的利用代表了目前交叉偶联方法的主要挑战。叔烷基格氏试剂与芳基溴的镍催化的Kumada交联使得这种困难的反应可与多种不同的底物进行。使用空间要求高的双功能N杂环卡宾配体可获得最佳结果。

  DOI：

  10.1002/chem.201100909

文献信息

• PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF- MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES
  申请人：EMS S. A.

  公开号：EP2418200A1

  公开（公告）日：2012-02-15

  The present invention relates to phthalimide derivatives of non-steroidal and/or TNF-α modulating anti-inflammatory compounds as well as the process of obtaining the so-called derivatives, pharmaceutical compositions containing such derivatives and their uses, including use in the treatment of inflammatory diseases, especially those related to chronic inflammatory processes, such as rheumatoid arthritis and intestinal inflammatory diseases (for instance, Chron's disease) and the use of the referred to pharmaceutical compositions as antipyretic, analgesic and platelet antiaggregating medications.

  本发明涉及非甾体类和/或 TNF-α 调节抗炎化合物的邻苯二甲酰亚胺衍生物，以及获得所谓衍生物的工艺、含有此类衍生物的药物组合物及其用途，包括用于治疗炎症性疾病，尤其是与慢性炎症过程有关的疾病，如类风湿性关节炎和肠道炎症性疾病（如慢性疾病），以及将所述药物组合物用作解热、镇痛和抗血小板聚集药物。
• Extended-release formulation for reducing the frequency of urination and method of use thereof
  申请人：Wellesley Pharmaceuticals, LLC

  公开号：EP2612663A1

  公开（公告）日：2013-07-10

  Compositions for reducing the frequency of urination are disclosed. One aspect of the present invention provides a pharmaceutical composition for reducing the frequency of urination, comprising: a first analgesic agent selected from the group consisting of aspirin, ibuprofen, naproxen sodium, indomethacin, nabumetone and acetaminophen, wherein said pharmaceutical composition is formulated in an extended-release formulation and wherein said first analgesic agent is administered orally at a daily dose of 5 mg to 2000 mg. A further aspect provides a pharmaceutical composition for reducing the frequency of urination, comprising: a first component formulated for immediate-release; and a second component formulated for extended-release, wherein said first component and said second component each comprises one or more analgesic agents selected from the group consisting of aspirin, ibuprofen, naproxen sodium, indomethacin, nabumetone and acetaminophen, and wherein each analgesic agent in said first component and said second component is administered orally at a daily dose of 5 mg to 2000 mg. Another aspect provides a pharmaceutical composition, comprising: one or more analgesic agents selected from the group consisting of aspirin, ibuprofen, naproxen sodium, indomethacin, nabumetone and acetaminophen; an antidiuretic agent; and a pharmaceutically acceptable carrier, wherein said pharmaceutical composition is formulated for extended-release in an oral dosage form, and wherein the total dosage of said one or more analgesic agents is 5 mg to 1000 mg.

  本发明公开了用于减少排尿次数的组合物。本发明的一个方面提供了一种用于降低排尿频率的药物组合物，包括：选自阿司匹林、布洛芬、萘普生钠、吲哚美辛、萘丁美酮和对乙酰氨基酚组成的组的第一镇痛剂，其中所述药物组合物配制成缓释制剂，并且所述第一镇痛剂以 5 毫克至 2000 毫克的每日剂量口服给药。另一个方面提供了一种用于减少尿频的药物组合物，包括：配制成速释制剂的第一成分；和配制成缓释制剂的第二成分，其中所述第一成分和所述第二成分各自包含一种或多种镇痛剂，这些镇痛剂选自由阿司匹林、布洛芬、萘普生钠、吲哚美辛、萘丁美酮和对乙酰氨基酚组成的组，并且所述第一成分和所述第二成分中的每种镇痛剂的口服日剂量为 5 毫克至 2000 毫克。另一个方面提供了一种药物组合物，其中包含：一种或多种镇痛剂，选自由阿司匹林、布洛芬、萘普生钠、吲哚美辛、萘丁美酮和对乙酰氨基酚组成的组；一种抗利尿剂；以及一种药学上可接受的载体，其中所述药物组合物配制成缓释口服剂型，且所述一种或多种镇痛剂的总剂量为 5 毫克至 1000 毫克。
• Delayed release formulation for reducing the frequency of urination and method of use thereof
  申请人：Wellesley Pharmaceuticals, LLC

  公开号：EP2612661A1

  公开（公告）日：2013-07-10

  Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in a delayed-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent.

  本文公开了减少排尿次数的方法和组合物。一种方法包括向有需要的受试者施用有效量的药物组合物，该药物组合物包含以缓释制剂配制的镇痛剂。另一种方法包括向有需要的受试者施用有效量的药物组合物，该组合物包含多种活性成分。另一种方法包括向有需要的受试者施用有效量的利尿剂，然后再施用另一种包含镇痛剂的药物组合物。
• Pharmaceutical formulation for reducing frequency of urination and method of use thereof
  申请人：WELLESLEY PHARMACEUTICALS, LLC

  公开号：US10010514B2

  公开（公告）日：2018-07-03

  Methods and compositions for reducing frequency of urination are disclosed. The methods comprise administering to a subject having a condition that resulting in undesired frequency of urination an effective amount of a pharmaceutical composition comprising one or more prostaglandin pathway inhibitors. The pharmaceutical compositions comprise one or more prostaglandin pathway inhibitors and a pharmaceutically acceptable carrier.

  本发明公开了减少尿频的方法和组合物。这些方法包括向有导致不希望的尿频症状的受试者施用有效量的药物组合物，该药物组合物包含一种或多种前列腺素途径抑制剂。药物组合物包括一种或多种前列腺素途径抑制剂和药学上可接受的载体。
• Composition for reducing frequency of urination, method of making and use thereof
  申请人：WELLESLEY PHARMACEUTICALS, LLC

  公开号：US10105328B2

  公开（公告）日：2018-10-23

  Pharmaceutical compositions for reducing frequency of urination are disclosed. The pharmaceutical compositions comprise one or more prostaglandin pathway inhibitors and a pharmaceutically acceptable carrier. Also disclosed are methods of making and using the pharmaceutical compositions.

  本发明公开了用于减少尿频的药物组合物。这些药物组合物包含一种或多种前列腺素通路抑制剂和药学上可接受的载体。还公开了制造和使用药物组合物的方法。